Previous 10 | Next 10 |
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the publication ...
-- Presentation to be webcast on Cortexyme’s website -- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other deg...
-- New results demonstrate P. gingivalis’ ability to infect neurons and cause characteristic Alzheimer’s pathology -- Cortexyme’s lead compound, COR388, targets gingipains produced by P. gingivalis and is currently under investigation in the Phase 2/3 GAIN Trial ...
Medtronic Gets Patent Challenge from Axonics Medtronic Plc ( MDT ) saw a small setback as Axonics Modulation Technologies filed a petition with the United States Patents and Trademark Office against one of its patents. The petitions contest the validity of Medtronic's patent related to s...
Cortexyme (NASDAQ: CRTX ): Q4 GAAP EPS of -$0.46 misses by $0.08 . Cash, cash equivalents, and short and long-term marketable securities of $116.6M. Press Release More news on: Cortexyme, Inc., Earnings news and commentary, Healthcare stocks news,
— Following initial public offering and private placement, Cortexyme is well capitalized and focused on high quality execution of the Phase 2/3 GAIN Trial — Interim analysis for the GAIN Trial on track to be completed before year-end 2020, with top-line results from stud...
- Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 Cortexyme, Inc. (Nasdaq: CR...
Thinly traded Cortexyme ( CRTX +4.4% ) is up, albeit on turnover of only 79K shares, in reaction to its update on lead candidate COR388, currently being evaluated in a Phase 2/3 clinical trial, GAIN , in patients with mild-to-moderate Alzheimer's disease dementia. More news on: Cortex...
- Interim analysis in the Phase 2/3 GAIN Trial expected to occur in Q4 2020 Cortexyme, Inc. (Nasdaq: CRTX) today provided an update on its clinical development plans for COR388, the company’s lead investigational medicine in development for mild to moderate Alzheimer’s di...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private placement offering. The Company issued 2,500,000 sha...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...